Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM
- PMID: 17188020
- DOI: 10.1016/j.ejheart.2006.10.012
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM
Abstract
Background: Limited comparative studies assessing the health-related quality of life (HRQL) in heart failure (HF) patients with preserved vs. low ejection fraction (LVEF) have been disparate.
Aims: The aims of this study were a) to characterize HRQL in a large population of HF patients with preserved and low LVEF and b) to determine the factors associated with worse HRQL.
Methods: Patients with symptomatic HF (NYHA Class II-IV) enrolled in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) HRQL study completed the Minnesota Living with Heart Failure questionnaire at randomization. Patients were stratified into 2 HF cohorts: preserved LVEF (>40%) and low LVEF (<or=40%).
Results: In 2709 of the eligible 2744 (98.6%) patients, the summary scores ranged from 0 to 105 (mean 40.9). There were no differences in overall responses of HF patients with preserved vs. low LVEF (41.1 vs. 40.8). Independent factors associated with worse HRQL in both populations included female gender, younger age, higher body mass index, lower systolic blood pressure, greater symptom burden, and worse functional status.
Conclusions: In symptomatic HF patients, HRQL is equally impaired in both preserved and low LVEF populations. Targeting improvement in symptoms and HRQL is an important treatment objective in all HF patients.
Similar articles
-
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).J Am Coll Cardiol. 2013 Nov 12;62(20):1845-54. doi: 10.1016/j.jacc.2013.05.072. Epub 2013 Jul 10. J Am Coll Cardiol. 2013. PMID: 23850914
-
Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme.Eur J Heart Fail. 2007 May;9(5):510-7. doi: 10.1016/j.ejheart.2006.11.006. Epub 2007 Feb 20. Eur J Heart Fail. 2007. PMID: 17317308
-
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.Circulation. 2004 Oct 26;110(17):2618-26. doi: 10.1161/01.CIR.0000146819.43235.A9. Epub 2004 Oct 18. Circulation. 2004. PMID: 15492298 Clinical Trial.
-
Angiotensin inhibition in heart failure.J Renin Angiotensin Aldosterone Syst. 2004 Sep;5 Suppl 1:S17-22. doi: 10.3317/jraas.2004.019. J Renin Angiotensin Aldosterone Syst. 2004. PMID: 15526237 Review.
-
The CHARM program: the effects of candesartan for the management of patients with chronic heart failure.Expert Rev Cardiovasc Ther. 2009 Jan;7(1):9-16. doi: 10.1586/14779072.7.1.9. Expert Rev Cardiovasc Ther. 2009. PMID: 19105762 Review.
Cited by
-
Differences in Health-Related Quality of Life among Patients with Heart Failure.Medicina (Kaunas). 2024 Jan 6;60(1):109. doi: 10.3390/medicina60010109. Medicina (Kaunas). 2024. PMID: 38256370 Free PMC article. Review.
-
Accelerometer vs. other activity measures in heart failure with preserved ejection fraction: the VITALITY-HFpEF trial.ESC Heart Fail. 2024 Feb;11(1):293-298. doi: 10.1002/ehf2.14572. Epub 2023 Nov 20. ESC Heart Fail. 2024. PMID: 37985002 Free PMC article. Clinical Trial.
-
Type D personality is a predictor of poor emotional quality of life in primary care heart failure patients independent of depressive symptoms and New York Heart Association functional class.J Behav Med. 2010 Feb;33(1):72-80. doi: 10.1007/s10865-009-9236-1. J Behav Med. 2010. PMID: 19937107 Free PMC article.
-
End of life care in advanced heart failure.Curr Treat Options Cardiovasc Med. 2011 Feb;13(1):79-89. doi: 10.1007/s11936-010-0100-y. Curr Treat Options Cardiovasc Med. 2011. PMID: 21221915
-
The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction.Curr Heart Fail Rep. 2016 Feb;13(1):47-59. doi: 10.1007/s11897-016-0277-9. Curr Heart Fail Rep. 2016. PMID: 26792295 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous